Lipella Pharmaceuticals INC 8-K filings

Lipella Pharmaceuticals Inc. has filed for Chapter 11 bankruptcy and entered into an Asset Purchase Agreement to sell substantially all of its assets.

Lori A. Birder has resigned from Lipella Pharmaceuticals Inc.'s Board of Directors, effective immediately, with no reported disagreements.

Dr. Naoki Yoshimura will retire from Lipella Pharmaceuticals Inc.'s Board of Directors effective December 31, 2025.

Dr. Michael Chancellor will retire from his Chief Medical Officer and Board of Directors roles at Lipella Pharmaceuticals Inc. effective December 4, 2025.

Lipella Pharmaceuticals announced positive final results from its Phase 2a study of LP-10 for oral lichen planus, meeting safety and efficacy endpoints.

Lipella Pharmaceuticals Inc. issued a letter to stockholders addressing its recent Nasdaq delisting, reaffirming operational strength, and detailing plans to relist on a national exchange while advancing its clinical pipeline.

Lipella Pharmaceuticals Inc. announced its common stock has been delisted from the Nasdaq Capital Market effective June 20, 2025, due to non-compliance with shareholder approval and voting rights rules related to recent private placement transactions.

Lipella Pharmaceuticals Inc. has announced its 2025 annual meeting of stockholders will be held on July 21, 2025, with a record date of June 18, 2025, and updated deadlines for stockholder proposals.

Lipella Pharmaceuticals received a notification from Nasdaq regarding non-compliance with listing rules due to the issuance of Series C Preferred Stock and warrants.

Lipella Pharmaceuticals reports statistically significant safety and efficacy data from its Phase 2a trial of LP-310 for Oral Lichen Planus, to be presented at the 2025 AAOM/EAOM International Meeting.

Lipella Pharmaceuticals believes it has regained compliance with Nasdaq's Stockholders' Equity Requirement following recent private placement offerings.

Lipella Pharmaceuticals amends its certificate of designation to increase the number of Series C Voting Convertible Preferred Stock shares from 1,050,000 to 1,260,000.

Lipella Pharmaceuticals has entered into an agreement with H.C. Wainwright & Co., LLC to sell up to $2.64 million of its common stock through an at-the-market offering.

Lipella Pharmaceuticals completes a $6 million private placement of Series B Preferred Stock and launches an offering of warrants to purchase additional shares, aiming to bolster working capital.

Lipella Pharmaceuticals finalized the fourth closing of its private placement offering, generating $726,000 in gross proceeds through the sale of Series B Preferred Stock.

Lipella Pharmaceuticals completed the third closing of its private placement offering, raising $3.788 million through the sale of Series B Preferred Stock.

Lipella Pharmaceuticals modifies its agreement with Spartan Capital Securities, increasing the potential Mirror Offering size and adjusting restrictions on variable rate transactions.

Lipella Pharmaceuticals reports positive topline Phase 2a results for LP-310 in treating oral lichen planus (OLP) and receives FDA approval for an expanded access program for the same drug.

Lipella Pharmaceuticals has been granted continued listing on the Nasdaq Capital Market, contingent on meeting specific equity and fundraising milestones by April 14, 2025.

Lipella Pharmaceuticals finalized the second closing of its private placement, issuing additional shares of Series B preferred stock and securing $368,000 in gross proceeds.

Lipella Pharmaceuticals successfully closed the initial phase of its private offering, raising $2.2 million through the sale of Series B preferred stock.

Lipella Pharmaceuticals' special stockholder meeting was cancelled on December 27, 2024, due to the absence of a quorum.

Lipella Pharmaceuticals' special stockholder meeting was adjourned due to a lack of quorum and will reconvene on December 27, 2024.

Lipella Pharmaceuticals has entered into agreements with Spartan Capital Securities for a private placement of up to $6 million in convertible preferred stock, along with advisory services.

Lipella Pharmaceuticals' special meeting of stockholders was adjourned due to a lack of quorum and will reconvene on December 20, 2024.

Lipella Pharmaceuticals has completed a one-for-eight reverse stock split of its common stock, effective November 7, 2024.

Lipella Pharmaceuticals will implement a 1-for-8 reverse stock split on November 7, 2024, to meet Nasdaq's minimum bid price requirement.

Lipella Pharmaceuticals is appealing a Nasdaq delisting notice due to non-compliance with minimum share price and stockholders' equity requirements.

Lipella Pharmaceuticals held its 2024 Annual Meeting, electing directors, approving a reverse stock split, and ratifying the appointment of its accounting firm.

Lipella Pharmaceuticals received a notice from Nasdaq for failing to meet the minimum stockholders' equity requirement and must submit a plan to regain compliance by October 7, 2024.